Business Description
Biosergen AB
ISIN : SE0026821852
Total Employee Number:
1Compare
Compare
Traded in other countries / regions
BIOSGN.Sweden8N10.Germany IPO Date
2021-06-24Description
Biosergen AB is a clinical-stage biotechnology company advancing the treatment of life-threatening fungal infections. It has developed the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 is a drug in the field of antifungals because of its fungicidal effect (it kills the fungus), which is preferable to drugs with a fungistatic effect.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.59 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.9 | |||||
3-Year EPS without NRI Growth Rate | 36.9 | |||||
3-Year FCF Growth Rate | 34.5 | |||||
3-Year Book Growth Rate | -46 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.01 | |||||
9-Day RSI | 40.98 | |||||
14-Day RSI | 40.93 | |||||
3-1 Month Momentum % | -51.07 | |||||
6-1 Month Momentum % | -88.52 | |||||
12-1 Month Momentum % | -90.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.46 | |||||
Quick Ratio | 2.46 | |||||
Cash Ratio | 1.91 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -130.63 | |||||
ROA % | -111.15 | |||||
ROIC % | -1041.26 | |||||
3-Year ROIIC % | 214.24 | |||||
ROC (Joel Greenblatt) % | -2792.69 | |||||
ROCE % | -130.76 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.2 | |||||
Price-to-Tangible-Book | 1.2 | |||||
EV-to-Forward-EBIT | -6.76 | |||||
EV-to-FCF | -0.01 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.93 | |||||
Earnings Yield (Greenblatt) % | 2863.85 | |||||
FCF Yield % | -252.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biosergen AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -17.31 | ||
| Beta | 0.4707 | ||
| 3-Year Sharpe Ratio | -0.24 | ||
| 3-Year Sortino Ratio | -0.39 | ||
| Volatility % | 89.03 | ||
| 14-Day RSI | 40.93 | ||
| 14-Day ATR (kr) | 0.300762 | ||
| 20-Day SMA (kr) | 6.195 | ||
| 12-1 Month Momentum % | -90.36 | ||
| 52-Week Range (kr) | 4.28 - 55.2 | ||
| Shares Outstanding (Mil) | 2.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biosergen AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biosergen AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-18 | In 109 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 18 days | ||
| General meeting for 2025 | 2026-06-30 14:00 | 4.66 (-28.31%) | ||
| Annual report for 2025 | 2026-06-09 | 8.10 (-6.36%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 9.50 (-2.56%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-10 | 43.60 (-3.96%) | ||
| 0.01:1 Stock Split | 2025-12-01 | 46.80 (+1.74%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 47.50 (-5.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 50.40 (+0.00%) | ||
| General meeting for 2024 | 2025-06-11 11:00 | 64.80 (-3.28%) |
Show
Entries
Biosergen AB Frequently Asked Questions
What is Biosergen AB(OSTO:BIOSGN)'s stock price today?
The current price of OSTO:BIOSGN is kr6.00. The 52 week high of OSTO:BIOSGN is kr55.20 and 52 week low is kr4.28.
When is next earnings date of Biosergen AB(OSTO:BIOSGN)?
The next earnings date of Biosergen AB(OSTO:BIOSGN) is 2026-08-19.
Does Biosergen AB(OSTO:BIOSGN) pay dividends? If so, how much?
Biosergen AB(OSTO:BIOSGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Biosergen AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers